PMID- 31593848
OWN - NLM
STAT- MEDLINE
DCOM- 20200406
LR  - 20200408
IS  - 1873-5487 (Electronic)
IS  - 0188-4409 (Linking)
VI  - 50
IP  - 5
DP  - 2019 Jul
TI  - Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form 
      in Type 2 Diabetic Kidney Disease.
PG  - 249-256
LID - S0188-4409(19)30828-8 [pii]
LID - 10.1016/j.arcmed.2019.08.007 [doi]
AB  - BACKGROUND: Urokinase-type plasminogen activator receptor (uPAR) and its soluble 
      form (suPAR) are new injury biomarkers that have been recently suggested to play 
      a vital role in renal diseases. AIM AND METHODS: We evaluated the expression of 
      uPAR and the serum concentration of suPAR in type 2 diabetes (T(2)DM) patients 
      with diabetic kidney disease (DKD) to determine the role of this molecule as a 
      biomarker in DKD. The uPAR immunohistochemical staining was performed in 
      biopsy-confirmed DKD renal tissues. Meanwhile, the serum suPAR, Interleukin-18 
      (IL-18) and C-reactive protein (CRP) levels of 70 diabetic patients with or 
      without DKD and 15 healthy controls were measured. RESULTS: The uPAR expression 
      in DKD patients was significantly increased compared to that in healthy controls 
      and was widely colocalized with the podocyte marker WT1. Meanwhile, serum suPAR 
      and IL-18 levels gradually increased as DKD progressed to the advanced stage. 
      Moreover, serum suPAR and IL-18 levels were negatively correlated with eGFR 
      (rho = ‒0.734, rho = ‒0.462, p <0.01) and positively correlated with the urine 
      protein to creatinine ratio (UP/CR) (rho = 0.730, rho = 0.440, p <0.01). The suPAR 
      AUC performed better than the IL-18 AUC for the diagnosis of proteinuria (0.845 
      vs. 0.753, p <0.01) and the decline of renal function (0.895 vs. 0.796, p <0.01). 
      CONCLUSIONS: The uPAR expressed in the renal tissues of DKD patients. The soluble 
      form of uPAR, suPAR, can be detected in the serum of DKD patients and has a 
      better diagnostic efficiency in the diagnosis of proteinuria and renal 
      dysfunction in patients with T(2)DM than that of IL-18.
CI  - Copyright (c) 2019 IMSS. Published by Elsevier Inc. All rights reserved.
FAU - Zhou, Yujing
AU  - Zhou Y
AD  - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China; 
      Institute of Endocrinology and Metabolism, Shandong University, Jinan, China; Key 
      Laboratory of Endocrinology and Metabolism, Shandong Province in Medicine and 
      Health, Jinan, China; Department of Nuclear Medicine, Huashan Hospital, Fudan 
      University, Shanghai, China.
FAU - Ren, Jianmin
AU  - Ren J
AD  - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China; 
      Institute of Endocrinology and Metabolism, Shandong University, Jinan, China; Key 
      Laboratory of Endocrinology and Metabolism, Shandong Province in Medicine and 
      Health, Jinan, China.
FAU - Li, Peng
AU  - Li P
AD  - Department of Nephrology, Yuhuangding Hospital Affiliated to Qingdao University, 
      Yantai, China.
FAU - Ma, Rong
AU  - Ma R
AD  - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China; 
      Institute of Endocrinology and Metabolism, Shandong University, Jinan, China; Key 
      Laboratory of Endocrinology and Metabolism, Shandong Province in Medicine and 
      Health, Jinan, China.
FAU - Zhou, Mengkun
AU  - Zhou M
AD  - Department of Nephrology, Qilu Hospital of Shandong University, Jinan, China.
FAU - Zhang, Ningxin
AU  - Zhang N
AD  - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China; 
      Institute of Endocrinology and Metabolism, Shandong University, Jinan, China; Key 
      Laboratory of Endocrinology and Metabolism, Shandong Province in Medicine and 
      Health, Jinan, China.
FAU - Kong, Xiangguo
AU  - Kong X
AD  - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China; 
      Institute of Endocrinology and Metabolism, Shandong University, Jinan, China; Key 
      Laboratory of Endocrinology and Metabolism, Shandong Province in Medicine and 
      Health, Jinan, China.
FAU - Hu, Zhao
AU  - Hu Z
AD  - Department of Nephrology, Qilu Hospital of Shandong University, Jinan, China.
FAU - Xiao, Xiaoyan
AU  - Xiao X
AD  - Department of Nephrology, Qilu Hospital of Shandong University, Jinan, China. 
      Electronic address: xiaoyanxiao2007@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191005
PL  - United States
TA  - Arch Med Res
JT  - Archives of medical research
JID - 9312706
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, Urokinase Plasminogen Activator)
SB  - IM
MH  - Biomarkers/*blood
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Nephropathies/*genetics/pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Receptors, Urokinase Plasminogen Activator/*metabolism
OTO - NOTNLM
OT  - Diabetic kidney disease
OT  - Soluble urokinase-type plasminogen activator receptor
OT  - Type 2 diabetes mellitus
OT  - Urokinase-type plasminogen activator receptor
EDAT- 2019/10/09 06:00
MHDA- 2020/04/09 06:00
CRDT- 2019/10/09 06:00
PHST- 2019/08/14 00:00 [received]
PHST- 2019/08/21 00:00 [accepted]
PHST- 2019/10/09 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
PHST- 2019/10/09 06:00 [entrez]
AID - S0188-4409(19)30828-8 [pii]
AID - 10.1016/j.arcmed.2019.08.007 [doi]
PST - ppublish
SO  - Arch Med Res. 2019 Jul;50(5):249-256. doi: 10.1016/j.arcmed.2019.08.007. Epub 
      2019 Oct 5.